U.S. Home Infusion Therapy Market Size, Share & COVID-19 Impact Analysis, By Product (Devices, Drugs, and Services), By Indication (Enteral Nutrition, Anti-Infective, Chemotherapy, Hydration Therapy, Total Parenteral Nutrition, Immunoglobulins, and Others) and Forecast, 2023-2030

The U.S. home infusion therapy market size was valued at USD 17.26 billion in 2022 and is projected to grow from USD 18.82 billion in 2023 to USD 33.20 billion by 2030, exhibiting a CAGR of 8.4% during the forecast period.

Home infusion therapy includes the administration of medications through an intravenous or subcutaneous route to an individual at home. It has been proven to be a safe and effective alternative to patient care at hospitals. Also, home infusion therapy is anticipated to be one of the sectors in the home healthcare industry to witness faster growth prospects. For instance, according to the National Home Infusion Foundation (NHIF), the home infusion industry has seen an increase of 310% from 2010-2019.

This trend of medical care at home is expected to continue and strengthen in the coming years.The key factors driving this trend include the increasing prevalence of chronic diseases resulting in the high number of patients requiring such therapies, the ageing population,the expansion of remote patient monitoring (RPM) reimbursement codes and the high cost of hospital stays. In addition, growing number of therapies becoming available for patients, increasing number of infusion drugs in the pipeline, and expansion of clinical applications of current therapies have also contributed to the overall growth of this market.

COVID-19 IMPACT

Shift Towards Homecare Settings Amid COVID-19 to Propel Market Growth

The outbreak of COVID-19 had a positive impact on this market. Key market players witnessed a considerable growth in their revenues from home infusion therapy services owing to the significant increase in the number of patients receiving infusion therapy at home during the COVID-19 restrictions.

• For instance, OptumRx (Optum Inc.) generated a revenue of USD 87,498 million in 2020, an increase of 17.8% compared to 2019. This growth is attributed to higher volumes of people served through home infusion services and increased utilization of their pharmacy care services.

Furthermore, devices such as infusion pumps also witnessed increased demand in 2021, similar to 2020. Several factors such as the use of infusion pumps for COVID-19 patients, and emergency use authorization (EUA) for monoclonal antibody treatments by the U.S. FDA have resulted in increased demand for these devices in 2021. Moreover, Centers for Medicare & Medicaid Services (CMS) approval for home infusion therapy of monoclonal antibodies to COVID-19 patients played an important role in driving this demand through favorable reimbursement framework.

Also, various new implementations in terms of these therapy regulations to provide easy access to the services to the patient population during the pandemic have contributed to the significant growth of home-care services.

• For instance, in August 2021, a new bipartisan legislation introduced a new bill to help providers with reimbursement for in-home infusion treatments for conditions such as heart failure, cancer and immune diseases. The bill known as “The Preserving Patient Access to Home Infusion Act” would provide a new benefit under Medicare Part B, removing the requirement that a provider is to be physically present when a patient receives their infusions.

Such changes in regulations are anticipated to increase the adoption of these products & services leading to steady growth from 2022 onwards.

LATEST TRENDS 

Request a Free sample to learn more about this report.

Growing Therapy Diversity and Demand for These Services to Aid Market Expansion

U.S. home infusion therapy market growth in recent years has been driven by the concept of in-home infusion therapy which has gained momentum in various therapy areas, including oncology. Amidst the COVID-19 pandemic, several oncology centers in the U.S. launched and expanded their in-home cancer therapy infusion programs.  In addition, more therapies are also being moved to homecare settings, supporting the shift of care at home.

• For instance, in 2020, the Penn Center for Cancer Care Innovation provided at-home oncology treatments for 1,500 patients. The Center had aimed to serve at least the same number of patients in the year 2021.

Moreover, the clinical applications of currently available infusion therapies are also expanding. As per a resource by the U.S. National Library of Medicine, the number of infusion drugs in Phase I/II development is more than 280 and more than 100 drugs are in Phase III review. Additionally, according to BioSupply Trends Quarterly Magazine in July 2020, the sale of intravenous immunoglobulin (IVIG) has grown tenfold since 1990. This indicates the high demand for intravenous immunoglobulin therapies among patients. Thus, increase in demand for home infusion therapy in recent years  is expected to boost the market growth throughout the forecast period.

DRIVING FACTORS

Dramatic Shift Towards Home Healthcare to Boost Market Proliferation

With the rapidly evolving healthcare industry, patient care is moving out of hospitals & into homes. Rising ageing population in countries such as the U.S. is a major factor driving this change in the delivery of healthcare.

• For instance, as per the U.S. Census Bureau’s Population Projections, the number of U.S. individuals aged between 65 & above is expected to increase by twofold from 52 million in 2018 to 95 million by 2060. This age group is expected to hold a share of 23% in 2060. Such demographic trends are expected to lead to the market growth in the forecast period.

Furthermore, as per the Centers for Disease Control and Prevention (CDC) data, 70% of individuals receiving homecare are aged 65 and above. Moreover, according to the Medicare Payment Advisory Commission, Medicare enrollment is anticipated to witness a growth of over 50% in the next 15 years, reaching over 80 million in 2030 from 54 million beneficiaries in 2015. In 2022, more than 28 million individuals were enrolled in a Medicare Advantage plan. This shows an overall ageing of the U.S. population. Furthermore, the emergence of market players with portable and mobile devices for patients in homecare settings, along with flexible payment plans and rental plans to facilitate and cater to the growing shift of patients from hospitals to home healthcare, has also boosted the market growth.

• For instance, in March 2022, China’s National Medical Products Administration (NMPA) approved MicroPort Lifesciences’ new AutoEx portable Chemotherapy Infusion Pump.

Economic and Clinical Benefits of Home Infusion Therapies to Boost the Demand for These Services

There is a marked focus from government and other healthcare agencies towards the promotion of infusion therapy services to patients in homecare settings. This is owing to rising economic burden of treatment in hospitals and other healthcare facilities, along with shortage of healthcare resources including physicians, hospital beds, etc. This has led to an increasing number of patients opting for treatment at homecare settings in the U.S.

Additionally, these therapies cost less than the care provided in the hospital care setting. Homecare eliminates various cost components such as hospital visits, hospital inpatient stays, examination charges, and other miscellaneous charges including the drugs and devices charges.

• For instance, according to various studies, the cost of an intravenous immunoglobulin (IVIG) infusion in the homecare setting at Accredo, an U.S. based company, is 62% lower than medical office administration costs and 87% lower than hospital outpatient administration costs.


• Similarly, according to an article published by NCBI in July 2022, around 40% of these services can be effectively provided in home care settings.

Significantly lower costs (per episode) for infusion therapy at homecare settings is facilitating the shift of patients towards homecare settings. This is also driving the growth of the market in the U.S.

RESTRAINING FACTORS

Safety Concerns Coupled with Resistance Among Patient Population to Limit Market Proliferation

Even though the number of patients served by these services is large and is constantly growing, there are some factors that are limiting market growth in the U.S. These factors include opposition by physicians, safety concerns associated with the administration of these therapies, and the potential impact on community practices. Both patients and physicians have concerns about these therapies. The absence of a direct physician in the homecare setting may result in the potential risk of adverse events during infusion and general drug toxicity. Moreover, risk management is also especially problematic in homecare since all the required healthcare workplace protections for both patients and caregivers may not be readily available.

Furthermore, the American Society of Clinical Oncology (ASCO) has also expressed concerns regarding the safety of routinely administered oncology drugs at patients’ homes. Similarly, the Community Oncology Alliance (COA) also opposes infusion therapy at home for oncology treatments. Therefore, the confluence of the above-mentioned factors, along with the presence of an inadequate reimbursement scenario, is likely to impede the market growth throughout the forecast period.

SEGMENTATION

By Product Analysis

To know how our report can help streamline your business, Speak to Analyst

Drugs Segment to Dominate the Market Owing to Increasing Regulatory Approvals

Based on product, the U.S. market is categorized into devices, drugs, and services.

The drugs segment captured the largest market share in 2022 and is expected to exhibit a noteworthy CAGR during the forecast period. The dominance of this segment is associated with the increasing number of regulatory approvals for these products, high prevalence of chronic diseases, and high risk of hospital acquired infections amongst the U.S. population.

• For instance, in June 2020, the U.S. FDA approved Phesgo to treat patients with HER2-positive breast cancer in combination with chemotherapy. This drug could be administered at home by a qualified healthcare professional only.

The services segment is anticipated to witness the fastest growth over the forecast period. This growth can be attributed to the expansion of service offerings and the implementation of various strategies and initiatives undertaken by key operating players to capture the untapped avenues of the market.

By Indication Analysis

High Prevalence of Gastrointestinal Diseases to Enable Enteral Nutrition Segment to Hold Major Market Share 

Based on indication, the market is classified into enteral nutrition, anti-infective, chemotherapy, hydration therapy, total parenteral nutrition, immunoglobulins, and others.

The enteral nutrition segment captured the highest market share in 2022. The increasing number of patients with chronic diseases such as gastrointestinal diseases and diabetes requiring enteral feeding has primarily driven the segment growth.

• For instance, according to a research article published by NCBI in July 2020, the prevalence of home enteral nutrition (HEN) is growing in the U.S. The prevalence has increased from 463 per million citizens in 1995 to 1,385 per million citizens in the U.S. in 2017.

The second most dominant segment is the anti-infective segment. The recent COVID-19 pandemic, along with the increasing prevalence of infectious diseases and easy administration of anti-infective therapies, are some of the factors that have contributed to the growth of the segment.

The chemotherapy segment is estimated to witness the highest growth rate during the forecast period. The rising prevalence of cancer in the U.S. coupled with robust efforts by the government, market players and healthcare organizations to introduce chemotherapy infusion therapy services at home is expected to boost the segment growth.

Other indications include hydration therapy, total parenteral nutrition (TPN), immunoglobulins, and others. These segments are anticipated to witness a steady growth throughout the forecast period.

KEY INDUSTRY PLAYERS

Option Care Health Inc. Leads the Market in 2022 with Strong Focus on Collaborations & Partnerships

The competitive landscape of this market is semi-consolidated in nature, as key companies such as Option Care Health Inc., Optum Inc., and CVS Health accounted for a significant proportion of U.S. home infusion therapy market share in 2022. Option Care Health Inc. is one of the leading players in the market. The company's prominent position in the market is due to its strong focus on mergers & acquisitions, new product launches and collaborations with an aim to expand its product portfolio. Moreover, a wide network across the U.S. to offer its home infusion services contributes to the strong market share of the company.

• For instance, in December 2022, Option Care Health Inc. partnered with WellSky to boost innovation in ambulatory & home infusion technology. This partnership is aimed at bringing new capabilities to WellSky’s CareTend – an infusion & specialty pharmacy platform.

Optum Inc. held a considerable market share in 2022. The introduction of advanced infusion services to increase the brand presence of the company, strong emphasis on partnerships and acquisitions with other major players to widen the portfolio and increase brand awareness are some factors that have strengthened the company’s market presence.

• For instance, in August 2022, OptumRx and Ringmaster Technologies collaborated to offer an advanced healthcare stop-loss procurement process. It is aimed to provide enhanced connectivity and increased transparency between third-party administrators, OptumRx and MGUs.

LIST OF KEY MARKET COMPANIES PROFILED:

• Option Care Health Inc. (U.S.)


• Optum Inc. (U.S.)


• CareCentrix Inc. (U.S.)


• CVS Health (U.S.)


• KabaFusion (U.S.)


• Promptcare Respiratory (U.S.)


• Baxter (U.S.)


• InfuSystem Holdings, Inc. (U.S.)


• Moog Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• November 2022 – Medtronic plc introduced an Extended infusion set with double the wear time. This set has a wear time up to 7 days.


• September 2022 - CarepathRx and Orlando Health signed a multi-year infusion management service agreement to offer high-quality home infusion services. This new service is convenient and cost-effective for patients.


• March 2022 - Fresenius Kabi completed the acquisition of Ivenix – a manufacturer of smart infusion pumps. This acquisition complemented the company’s infusion treatment offerings.


• January 2021 - OSU alumnus introduced a new technology, IV Ensure, aimed at revolutionizing at-home infusion treatment. The device uses remote monitoring to help patients monitor their health and improve compliance and health outcomes.


• February 2020 - Avoset developed a homecare system, AvosetGO, an infusion pump device with embedded touch screens which can be connected and watched over via smart devices.

REPORT COVERAGE

An Infographic Representation of U.S. Home Infusion Therapy Market

View Full Infographic

To get information on various segments, share your queries with us

The market report provides an in-depth analysis of the industry. It focuses on segments such as product and indication. Besides this, it offers insights related to the impact of COVID-19, market trends and highlights the technological advancements in this market. Additionally, the report consists of several factors that contributes to the growth of this market. The report also provides the competitive landscape of the market.

Report Scope & Segmentation